Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook

Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Castration-Resistant Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Prostate cancer (PCa) ranks among the most prevalent malignancies worldwide. Typically, men newly diagnosed with PCa exhibit localized disease and commonly undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Within a decade, a variable proportion of these patients develop castration-resistant prostate cancer (CRPC). For individuals with metastatic castration-resistant prostate cancer (MCRPC), the outlook is bleak, as it is considered incurable with a relatively poor prognosis. The median survival for CRPC ranges from 9 to 30 months, diminishing further to 9 to 13 months for those with MCRPC. Effective therapeutic approaches for MCRPC include cytotoxic chemotherapy agents, AR-blocking agents, immunotherapies, and radiopharmaceuticals. Taxane chemotherapy, including docetaxel and cabazitaxel, stands as the standard treatment for MCRPC.

• In the USA, the incidence of prostate cancer (PCa) falls within the range of 95 to 112 cases per 100,000 population, constituting approximately 15% of all cancer cases. Furthermore, around 85% to 90% of patients presenting with new MCRPC issues have progressed from non-metastatic CRPC (nmCRPC).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: